Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PD-1 knockout engineered T cells - Chengdu MedGenCell

Next Previous
Drug Profile

PD-1 knockout engineered T cells - Chengdu MedGenCell

Latest Information Update: 17 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chengdu MedGenCell
  • Developer Anhui Provincial Hospital; Chengdu MedGenCell; West China Hospital Sichuan University
  • Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Gene silencing; Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Lung cancer; Malignant melanoma
  • No development reported Non-small cell lung cancer

Most Recent Events

  • 17 Mar 2020 Chengdu MedGenCell completes a phase I trial in Non-small cell lung cancer (Metastatic disease, Late-stage disease) in China (Parenteral) (NCT02793856)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease) in China (Parenteral)
  • 01 Jun 2018 Efficacy and adverse events data from a phase I trial in in Non-small cell lung cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top